Description: Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.
Home Page: www.zealandpharma.com
Sydmarken 11
Søborg,
2860
Denmark
Phone:
45 88 77 36 00
Officers
| Name | Title |
|---|---|
| Mr. Adam Sinding Steensberg M.D. | President & CEO |
| Ms. Henriette Wennicke | EVP & CFO |
| Mr. Ivan Mourits Moller | Executive VP & COO |
| Dr. David M. Kendall M.D. | Chief Medical Officer and Head of R&D |
| Mr. Mads Kronborg | Head of Investor Relations & Communication |
| Mr. Ravinder Singh Chahil | EVP & General Counsel |
| Ms. Christina Sonnenborg Bredal | Executive VP & Chief People Officer |
| Dr. Jens Damsgaard Mikkelsen M.D. | Head of Molecular Pharmacology |
| Dr. Danilo Verge | Head of Global Medical Affairs |
| Lykke Romer | VP & Head of Finance and Accounting |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 6.0501 |
| Price-to-Sales TTM: | 93.7425 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 298 |